Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.070
-0.060 (-5.31%)
Mar 5, 2026, 10:15 AM EST - Market open
Heron Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Heron Therapeutics stock have an average target of 4.50, with a low estimate of 3.00 and a high estimate of 6.00. The average target predicts an increase of 320.56% from the current stock price of 1.07.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 9, 2026.
Analyst Ratings
The average analyst rating for Heron Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +460.75% | Jan 9, 2026 |
| Needham | Needham | Strong Buy Maintains $4 → $3 | Strong Buy | Maintains | $4 → $3 | +180.37% | Aug 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +460.75% | Jun 9, 2025 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +273.83% | Apr 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +273.83% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
178.57M
from 154.90M
Increased by 15.28%
Revenue Next Year
214.81M
from 178.57M
Increased by 20.29%
EPS This Year
n/a
from -0.12
EPS Next Year
0.12
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 186.5M | 240.0M | |||
| Avg | 178.6M | 214.8M | |||
| Low | 169.5M | 188.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 20.4% | 34.4% | |||
| Avg | 15.3% | 20.3% | |||
| Low | 9.4% | 5.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.03 | 0.12 | |
| Avg | - | 0.12 | |
| Low | -0.03 | 0.11 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.